Corona Remedies' Q4 FY 2025-26 Quarterly Results

Result Summary

• Corona Remedies Ltd reported a 3.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were up by 12.0% QoQ and - - YoY.
• The net profit increased 9.8% QoQ and - - YoY.
• The earnings per share (EPS) of Corona Remedies Ltd stood at 7.41 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Corona Remedies Ltd is a pharmaceutical company based in India. It operates primarily in the healthcare sector, focusing on the development, production, and marketing of a wide range of pharmaceutical products. The company is known for its diverse portfolio that includes generic medicines, over-the-counter drugs, and other healthcare products. As of the most recent information available, specific recent developments or strategic initiatives have not been detailed. Therefore, any recent major developments are not available for review in this report.

Revenue

During Q4FY26, Corona Remedies Ltd reported a total income of ₹357.20 crores, representing a quarter-over-quarter increase of 3.6% compared to ₹344.66 crores in Q3FY26. There is no year-over-year comparison available due to the absence of data from Q4FY25. The steady QoQ growth in total income suggests a positive trajectory in the company's ability to generate revenue over the quarter. The revenue data indicates an upward trend in the company's financial performance on a quarterly basis.

Profitability

In Q4FY26, the company reported a profit before tax of ₹54.74 crores, which is a slight decrease of 0.8% from the previous quarter, where the profit before tax stood at ₹55.19 crores. The tax paid during this quarter was ₹9.41 crores, which is a significant reduction of 32.5% compared to the ₹13.94 crores paid in Q3FY26. After accounting for taxes, the profit after tax was ₹45.33 crores, an increase of 9.8% from ₹41.27 crores in Q3FY26. Correspondingly, the earnings per share also rose by 9.8% to ₹7.41 from ₹6.75 in the previous quarter. The data reflects a robust increase in net profitability, despite a marginal decline in profit before tax.

Operating Metrics

The total expenses for Corona Remedies Ltd in Q4FY26 amounted to ₹302.74 crores, marking a 12.0% increase from ₹270.37 crores in Q3FY26. This indicates a rise in the company's operating costs over the quarter. The substantial increase in expenses, coupled with a modest growth in revenue, resulted in a slight decline in the profit before tax. However, the decrease in tax payments contributed positively to the net profit figures. Such changes in operating metrics highlight the dynamics between income, expenses, and taxation that impact the company's overall financial health. The increased expenses may reflect strategic investments or cost escalations that the company experienced during the quarter.